Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048892 · ClinicalTrials.gov registry record · Phase 1
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01048892 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 22 participants.
The verdict
NCT01048892, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill even more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of Seneca Valley virus-001 in treating young patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cyclophosphamide
- OTHER pharmacological study
- BIOLOGICAL Seneca Valley virus-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01048892
The ClinicalTrials.gov registry entry for NCT01048892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01048892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01048892 about?
NCT01048892 is a clinical study titled "Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features". RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill even more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of Seneca Valley vi...
What is the current status of trial NCT01048892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-09.
What interventions are being tested in trial NCT01048892?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cyclophosphamide (DRUG), pharmacological study (OTHER), Seneca Valley virus-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01048892?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.